News - Lucentis, Bayer


Current filters:


Popular Filters

Asia-Pacific region macular degeneration market to see modest growth; report

Asia-Pacific region macular degeneration market to see modest growth; report


Due to the absence of promising products in the pipeline or expected new drug launches, the macular degeneration…

Asia-PacificBayerEyleaLucentisMacugenMarkets & MarketingNovartisOphthalmicsPfizerPharmaceuticalRegeneronRoche

BIA warns that UK government pricing proposals would damage UK biotech


The BioIndustry Association (BIA), the UK trade association for the innovative biotechnology sector,…


NICE "green light" for Bayer's Eylea as a treatment for wet AMD


UK drugs watch dog the National Institute for Health and Care Excellence (NICE) this morning (May 31)…


Avastin remains preferred DME therapy, despite Lucentis extended label in USA


Despite the approval of Swiss drug major Roche (ROG: SIX) subsidiary Genentech's Lucentis (ranibizumab…

AvastinBayerBiotechnologyEyleaGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

Novartis' Lucentis captures two-thirds of wet-AMD patient share in Europe


Retinal specialists in the EU5 (France, Germany, Italy, Spain and the UK) treat 66% of intravitreal-pharmaceutically-treated…

AvastinBayerBiotechnologyEuropeEyleaLucentisMarkets & MarketingNovartisOphthalmicsPharmaceuticalRoche

Trial and uptake of Regeneron's Eylea continues to rise among US retinal specialists; report


After six months on the market, 76% of retinal specialists in the USA have prescribed US biotech firm…

AvastinBayerEyleaLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

Regeneron and Bayer’s Eylea backed by thought leaders for DME


Based on clinical data and the opinions of interviewed thought leaders by health care advisory firm Decision…

AllerganBayerEyleaLucentisMarkets & MarketingNorth AmericaOphthalmicsOzurdexPharmaceuticalRegeneron

Back to top